

Dario Baratti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5001404/publications.pdf>

Version: 2024-02-01

151
papers

8,736
citations

34493

54
h-index

53065

89
g-index

158
all docs

158
docs citations

158
times ranked

4523
citing authors

#	ARTICLE	IF	CITATIONS
1	Systemic metastases from low-grade and high-grade pseudomyxoma peritonei: Treatments and outcomes. <i>European Journal of Surgical Oncology</i> , 2022, 48, 1590-1597.	0.5	6
2	An International Registry of Peritoneal Carcinomatosis from Appendiceal Goblet Cell Carcinoma Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. <i>World Journal of Surgery</i> , 2022, 46, 1336-1343.	0.8	1
3	miR-550a-3p is a prognostic biomarker and exerts tumor-suppressive functions by targeting HSP90AA1 in diffuse malignant peritoneal mesothelioma. <i>Cancer Gene Therapy</i> , 2022, 29, 1394-1404.	2.2	3
4	Preliminary results of a program for the implementation of laparoscopic colorectal surgery in an Italian comprehensive cancer center during the COVID-19 pandemic. <i>Updates in Surgery</i> , 2022, 74, 1271-1279.	0.9	1
5	Phase II randomized study on tissue distribution and pharmacokinetics of cisplatin according to different levels of intra-abdominal pressure (IAP) during HIPEC (NCT02949791). <i>European Journal of Surgical Oncology</i> , 2021, 47, 82-88.	0.5	16
6	Prognostic Impact of Primary Side and RAS/RAF Mutations in a Surgical Series of Colorectal Cancer with Peritoneal Metastases. <i>Annals of Surgical Oncology</i> , 2021, 28, 3332-3342.	0.7	19
7	Combined liver resection and cytoreductive surgery with HIPEC for metastatic colorectal cancer: Results of a worldwide analysis of 565 patients from the Peritoneal Surface Oncology Group International (PSOGI). <i>European Journal of Surgical Oncology</i> , 2021, 47, 89-100.	0.5	16
8	Comparative study of mucinous and non-mucinous appendiceal neoplasms with peritoneal dissemination treated by cyoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC). <i>European Journal of Surgical Oncology</i> , 2021, 47, 1132-1139.	0.5	12
9	Impact of Previous Gynecologic Surgical Procedures on Outcomes of Non-Gynecologic Peritoneal Malignancies Mimicking Ovarian Cancer: Less Is More?. <i>Annals of Surgical Oncology</i> , 2021, 28, 2899-2908.	0.7	5
10	ASO Author Reflections: Preoperative Staging for Nongynecological Peritoneal Malignancies Mimicking Ovarian Cancerâ€”Making the Omelet without Breaking the Eggs. <i>Annals of Surgical Oncology</i> , 2021, 28, 2909-2910.	0.7	0
11	The Role of Hyperthermic Intraperitoneal Chemotherapy in Pseudomyxoma Peritonei After Cytoreductive Surgery. <i>JAMA Surgery</i> , 2021, 156, e206363.	2.2	74
12	Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer with Synchronous Peritoneal Metastases: Multicenter Study of â€”Italian Peritoneal Surface Malignancies Oncoteamâ€”S.I.C.O.â€™. <i>Annals of Surgical Oncology</i> , 2021, 28, 9060-9070.	0.7	24
13	Patterns of peritoneal dissemination and response to systemic chemotherapy in common and rare peritoneal tumours treated by cytoreductive surgery: study protocol of a prospective, multicentre, observational study. <i>BMJ Open</i> , 2021, 11, e046819.	0.8	1
14	ASO Author Reflections: Prognostic Factors in Surgically Treated Peritoneal Metastases from Colorectal Cancer. <i>Annals of Surgical Oncology</i> , 2021, 28, 3343-3344.	0.7	0
15	Colorectal Peritoneal Metastases Treated by Perioperative Systemic Chemotherapy and Cytoreductive Surgery With or Without Mitomycin C-Based HIPEC: A Comparative Study Using the Peritoneal Surface Disease Severity Score (PSDSS). <i>Annals of Surgical Oncology</i> , 2020, 27, 98-106.	0.7	26
16	Management and complete resection of peritoneal and bone metastases from mucinous rectal carcinoma. <i>Tumori</i> , 2020, 107, 030089162097769.	0.6	1
17	Past, present and future of adjuvant HIPEC in patients at high risk for colorectal peritoneal metastases. <i>European Journal of Surgical Oncology</i> , 2020, 46, 737-739.	0.5	7
18	Hemodynamic and respiratory implications of high intra-abdominal pressure during HIPEC. <i>European Journal of Surgical Oncology</i> , 2020, 46, 1896-1901.	0.5	7

#	ARTICLE	IF	CITATIONS
19	Peritoneal Mesothelioma: Disease Biology and Patterns of Peritoneal Dissemination. , 2020, , 117-129.		2
20	Iterative cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: A multi-institutional experience. <i>Journal of Surgical Oncology</i> , 2019, 119, 336-346.	0.8	31
21	Clinico-pathological outcomes after total parietal peritonectomy, cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in advanced serous papillary peritoneal carcinoma submitted to neoadjuvant systemic chemotherapy- largest single institute experience. <i>European Journal of Surgical Oncology</i> , 2019, 45, 2103-2108.	0.5	10
22	Peritoneal Mesothelioma: Diagnosis and Management. , 2019, , 301-322.		0
23	RAS Mutation Decreases Overall Survival After Optimal Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy of Colorectal Peritoneal Metastasis: A Modification Proposal of the Peritoneal Surface Disease Severity Score. <i>Annals of Surgical Oncology</i> , 2019, 26, 2595-2604.	0.7	25
24	Metronomic Capecitabine With Cyclophosphamide Regimen in Unresectable or Relapsed Pseudomyxoma Peritonei. <i>Clinical Colorectal Cancer</i> , 2019, 18, e179-e190.	1.0	12
25	Molecular Signatures for Combined Targeted Treatments in Diffuse Malignant Peritoneal Mesothelioma. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5817.	1.8	11
26	Well differentiated papillary peritoneal mesothelioma treated by cytoreduction and hyperthermic intraperitoneal chemotherapy-the experience of the PSOGI registry. <i>European Journal of Surgical Oncology</i> , 2019, 45, 371-375.	0.5	13
27	Clinical Surveillance After Macroscopically Complete Surgery for Low-Grade Appendiceal Mucinous Neoplasms (LAMN) with or Without Limited Peritoneal Spread: Long-Term Results in a Prospective Series. <i>Annals of Surgical Oncology</i> , 2018, 25, 878-884.	0.7	55
28	Is Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy Justified for Biphasic Variants of Peritoneal Mesothelioma? Outcomes from the Peritoneal Surface Oncology Group International Registry. <i>Annals of Surgical Oncology</i> , 2018, 25, 667-673.	0.7	25
29	Multicystic mesothelioma: Operative and long-term outcomes with cytoreductive surgery and hyperthermic intra peritoneal chemotherapy. <i>European Journal of Surgical Oncology</i> , 2018, 44, 1100-1104.	0.5	24
30	Mesothelin and osteopontin as circulating markers of diffuse malignant peritoneal mesothelioma: A preliminary study. <i>European Journal of Surgical Oncology</i> , 2018, 44, 792-798.	0.5	21
31	Validation of the Recent PSOGI Pathological Classification of Pseudomyxoma Peritonei in a Single-Center Series of 265 Patients Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. <i>Annals of Surgical Oncology</i> , 2018, 25, 404-413.	0.7	61
32	ASO Author Reflections: Pathologic Classification of Pseudomyxoma Peritonei. <i>Annals of Surgical Oncology</i> , 2018, 25, 844-845.	0.7	1
33	Is there an oncological interest in the combination of CRS/HIPEC for peritoneal carcinomatosis of HCC? Results of a multicenter international study. <i>European Journal of Surgical Oncology</i> , 2018, 44, 1786-1792.	0.5	22
34	Learning Curve, Training Program, and Monitorization of Surgical Performance of Peritoneal Surface Malignancies Centers. <i>Surgical Oncology Clinics of North America</i> , 2018, 27, 507-517.	0.6	27
35	Dose-Dependent Effect of Red Blood Cells Transfusion on Perioperative and Long-Term Outcomes in Peritoneal Surface Malignancies Treated with Cytoreduction and HIPEC. <i>Annals of Surgical Oncology</i> , 2018, 25, 3264-3270.	0.7	20
36	Should a History of Extraperitoneal Disease Be a Contraindication to Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Cancer Peritoneal Metastases?. <i>Diseases of the Colon and Rectum</i> , 2018, 61, 1026-1034.	0.7	25

#	ARTICLE	IF	CITATIONS
37	Cytoreductive surgery and HIPEC improve survival compared to palliative chemotherapy for biliary carcinoma with peritoneal metastasis: A multi-institutional cohort from PSOGI and BIG RENAPE groups. <i>European Journal of Surgical Oncology</i> , 2018, 44, 1378-1383.	0.5	20
38	Multi-institutional study of peritoneal sarcomatosis from uterine sarcoma treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. <i>European Journal of Surgical Oncology</i> , 2017, 43, 2170-2177.	0.5	17
39	Hyperthermic Intraperitoneal Chemotherapy (HIPEC) at the Time of Primary Curative Surgery in Patients with Colorectal Cancer at High Risk for Metachronous Peritoneal Metastases. <i>Annals of Surgical Oncology</i> , 2017, 24, 167-175.	0.7	41
40	Cytoreductive Surgery and HIPEC in the First-Line and Interval Time Points of Advanced Epithelial Ovarian Cancer. <i>Indian Journal of Gynecologic Oncology</i> , 2017, 15, 11-20.	0.1	6
41	Colorectal Cancer Peritoneal Metastases. <i>Annals of Surgery</i> , 2016, 263, e5.	2.1	3
42	Pseudomyxoma Peritonei of Extra-Appendiceal Origin: A Comparative Study. <i>Annals of Surgical Oncology</i> , 2016, 23, 4222-4230.	0.7	30
43	The Role of Ki-67 and Pre-cytoreduction Parameters in Selecting Diffuse Malignant Peritoneal Mesothelioma (DMPM) Patients for Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC). <i>Annals of Surgical Oncology</i> , 2016, 23, 1468-1473.	0.7	59
44	Toward the molecular dissection of peritoneal pseudomyxoma. <i>Annals of Oncology</i> , 2016, 27, 2097-2103.	0.6	59
45	GNAS mutations as prognostic biomarker in patients with relapsed peritoneal pseudomyxoma receiving metronomic capecitabine and bevacizumab: a clinical and translational study. <i>Journal of Translational Medicine</i> , 2016, 14, 125.	1.8	36
46	Comment on the review entitled "A critical appraisal of hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of advanced and recurrent ovarian cancer" by Chiva LM and Gonzalez-Martin A.. <i>Gynecologic Oncology Reports</i> , 2016, 15, 7-8.	0.3	3
47	Progress in treatments for colorectal cancer peritoneal metastases during the years 2010-2015. A systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 100, 209-222.	2.0	92
48	The role of baseline inflammatory-based scores and serum tumor markers to risk stratify pseudomyxoma peritonei patients treated with cytoreduction (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). <i>European Journal of Surgical Oncology</i> , 2015, 41, 1097-1105.	0.5	22
49	Epidural analgesia for cytoreductive surgery with peritonectomy and heated intraperitoneal chemotherapy. <i>International Journal of Surgery</i> , 2015, 16, 99-106.	1.1	22
50	The role of hyperthermic intraperitoneal chemotherapy (HIPEC) and isolated perfusion (ILP) interventions in sarcoma. <i>Journal of Surgical Oncology</i> , 2015, 111, 570-579.	0.8	11
51	In Reply. <i>Oncologist</i> , 2015, 20, e5-e5.	1.9	1
52	Peritoneal Mesothelioma. <i>Updates in Surgery Series</i> , 2015, , 243-254.	0.0	0
53	Immunohistochemical Evaluation of Minichromosome Maintenance Protein 7 (MCM7), Topoisomerase III α , and Ki-67 in Diffuse Malignant Peritoneal Mesothelioma Patients Using Tissue Microarray. <i>Annals of Surgical Oncology</i> , 2015, 22, 4344-4351.	0.7	21
54	FOLFOX-4 Chemotherapy for Patients With Unresectable or Relapsed Peritoneal Pseudomyxoma. <i>Oncologist</i> , 2014, 19, 845-850.	1.9	48

#	ARTICLE	IF	CITATIONS
55	Prevention and early treatment of peritoneal metastases from colorectal cancer: Secondâ€look laparotomy or prophylactic HIPEC?. <i>Journal of Surgical Oncology</i> , 2014, 109, 225-226.	0.8	8
56	Postoperative Complications After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Affect Long-term Outcome of Patients With Peritoneal Metastases From Colorectal Cancer. <i>Diseases of the Colon and Rectum</i> , 2014, 57, 858-868.	0.7	106
57	Multicentre study of the learning curve and surgical performance of cytoreductive surgery with intraperitoneal chemotherapy for pseudomyxoma peritonei. <i>British Journal of Surgery</i> , 2014, 101, 1758-1765.	0.1	68
58	The American Society of Peritoneal Surface Malignancies evaluation of HIPEC with Mitomycin C versus Oxaliplatin in 539 patients with colon cancer undergoing a complete cytoreductive surgery. <i>Journal of Surgical Oncology</i> , 2014, 110, 779-785.	0.8	134
59	The American Society of Peritoneal Surface Malignancies (ASPSM) Multiinstitution Evaluation of the Peritoneal Surface Disease Severity Score (PSDSS) in 1,013 Patients with Colorectal Cancer with Peritoneal Carcinomatosis. <i>Annals of Surgical Oncology</i> , 2014, 21, 4195-4201.	0.7	141
60	Carboplatin plus paclitaxel scheduling for advanced ovarian cancer. <i>Lancet Oncology</i> , The, 2014, 15, e249.	5.1	3
61	The Role of Perioperative Systemic Chemotherapy in Diffuse Malignant Peritoneal Mesothelioma Patients Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. <i>Annals of Surgical Oncology</i> , 2013, 20, 1093-1100.	0.7	78
62	Diffuse malignant peritoneal mesothelioma: Long-term survival with complete cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC). <i>European Journal of Cancer</i> , 2013, 49, 3140-3148.	1.3	110
63	Primary peritoneal serous carcinoma treated by cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy. A multi-institutional study of 36 patients. <i>European Journal of Surgical Oncology</i> , 2013, 39, 742-747.	0.5	27
64	Learning curve for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal surface malignancies: Analysis of two centres. <i>Journal of Surgical Oncology</i> , 2013, 107, 312-319.	0.8	69
65	Circulating tumor markers: Predictors of incomplete cytoreduction and powerful determinants of outcome in pseudomyxoma peritonei. <i>Journal of Surgical Oncology</i> , 2013, 108, 1-8.	0.8	30
66	Secondary Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Recurrent Epithelial Ovarian Cancer. <i>Obstetrical and Gynecological Survey</i> , 2013, 68, 359-360.	0.2	0
67	Pilot study of adjuvant hyperthermic intraperitoneal chemotherapy in patients with colorectal cancer at high risk for the development of peritoneal metastases. <i>Tumori</i> , 2013, 99, 589-595.	0.6	11
68	Pilot study of adjuvant hyperthermic intraperitoneal chemotherapy in patients with colorectal cancer at high risk for the development of peritoneal metastases. <i>Tumori</i> , 2013, 99, 589-95.	0.6	9
69	Importance of gender in diffuse malignant peritoneal mesothelioma. <i>Annals of Oncology</i> , 2012, 23, 1494-1498.	0.6	47
70	Early- and Long-Term Outcome Data of Patients With Pseudomyxoma Peritonei From Appendiceal Origin Treated by a Strategy of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. <i>Journal of Clinical Oncology</i> , 2012, 30, 2449-2456.	0.8	873
71	Multidimensional Analysis of the Learning Curve for Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in Peritoneal Surface Malignancies. <i>Annals of Surgery</i> , 2012, 255, 348-356.	2.1	116
72	Identification of a Subgroup of Patients at Highest Risk for Complications After Surgical Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy. <i>Annals of Surgery</i> , 2012, 256, 334-341.	2.1	70

#	ARTICLE	IF	CITATIONS
73	The Importance of the Learning Curve and Surveillance of Surgical Performance in Peritoneal Surface Malignancy Programs. <i>Surgical Oncology Clinics of North America</i> , 2012, 21, 559-576.	0.6	30
74	Secondary cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent epithelial ovarian cancer: a multi-institutional study. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2012, 119, 800-809.	1.1	68
75	Cytoreductive Surgery with Selective Versus Complete Parietal Peritonectomy Followed by Hyperthermic Intraperitoneal Chemotherapy in Patients with Diffuse Malignant Peritoneal Mesothelioma: A Controlled Study. <i>Annals of Surgical Oncology</i> , 2012, 19, 1416-1424.	0.7	85
76	Advanced cytoreduction as surgical standard of care and hyperthermic intraperitoneal chemotherapy as promising treatment in epithelial ovarian cancer. <i>European Journal of Surgical Oncology</i> , 2011, 37, 4-9.	0.5	74
77	Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy as upfront therapy for advanced epithelial ovarian cancer: Multi-institutional phase-II trial. <i>Gynecologic Oncology</i> , 2011, 122, 215-220.	0.6	131
78	Diffuse malignant peritoneal mesothelioma: Systematic review of clinical management and biological research. <i>Journal of Surgical Oncology</i> , 2011, 103, 822-831.	0.8	62
79	Lymph Node Metastases in Diffuse Malignant Peritoneal Mesothelioma. <i>Annals of Surgical Oncology</i> , 2010, 17, 45-53.	0.7	72
80	In Reply: Five Reasons Why Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy Must Be Regarded as the New Standard of Care for Diffuse Malignant Peritoneal Mesothelioma. <i>Annals of Surgical Oncology</i> , 2010, 17, 1713-1714.	0.7	2
81	Peritoneal Sarcomatosis: Is There a Subset of Patients Who May Benefit from Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy?. <i>Annals of Surgical Oncology</i> , 2010, 17, 3220-3228.	0.7	83
82	Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in a Patient with Peritoneal Mesothelioma and HIV Infection. <i>Tumori</i> , 2010, 96, 340-344.	0.6	3
83	Pathophysiology and biology of peritoneal carcinomatosis. <i>World Journal of Gastrointestinal Oncology</i> , 2010, 2, 12.	0.8	74
84	Receptor tyrosine kinase and downstream signalling analysis in diffuse malignant peritoneal mesothelioma. <i>European Journal of Cancer</i> , 2010, 46, 2837-2848.	1.3	30
85	Cost analysis of the combined procedure of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC). <i>European Journal of Surgical Oncology</i> , 2010, 36, 463-469.	0.5	41
86	Multicystic peritoneal mesothelioma: outcomes and patho-biological features in a multi-institutional series treated by cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC). <i>European Journal of Surgical Oncology</i> , 2010, 36, 1047-1053.	0.5	37
87	Early and long-term postoperative management following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. <i>World Journal of Gastrointestinal Oncology</i> , 2010, 2, 36.	0.8	45
88	Experience with peritoneal mesothelioma at the Milan National Cancer Institute. <i>World Journal of Gastrointestinal Oncology</i> , 2010, 2, 76.	0.8	22
89	Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma: Multi-Institutional Experience. <i>Journal of Clinical Oncology</i> , 2009, 27, 6237-6242.	0.8	598
90	Surgical technique of parietal and visceral peritonectomy for peritoneal surface malignancies. <i>Journal of Surgical Oncology</i> , 2009, 100, 321-328.	0.8	91

#	ARTICLE	IF	CITATIONS
91	Diffuse Malignant Peritoneal Mesothelioma: Failure Analysis Following Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy (HIPEC). <i>Annals of Surgical Oncology</i> , 2009, 16, 463-472.	0.7	46
92	Circulating CA125 and diffuse malignant peritoneal mesothelioma. <i>European Journal of Surgical Oncology</i> , 2009, 35, 1198-1199.	0.5	14
93	Pseudomyxoma Peritonei. <i>Annals of Surgery</i> , 2009, 249, 243-249.	2.1	90
94	Surgical Treatment of Peritoneal Carcinomatosis. , 2009, , 229-236.		0
95	Drugs, carrier solutions and temperature in hyperthermic intraperitoneal chemotherapy. <i>Journal of Surgical Oncology</i> , 2008, 98, 247-252.	0.8	98
96	Locoregional treatment of peritoneal carcinomatosis from gastric cancer. <i>Journal of Surgical Oncology</i> , 2008, 98, 273-276.	0.8	77
97	Consensus statement on the loco regional treatment of colorectal cancer with peritoneal dissemination. <i>Journal of Surgical Oncology</i> , 2008, 98, 263-267.	0.8	180
98	Consensus statement on the loco regional treatment of appendiceal mucinous neoplasms with peritoneal dissemination (pseudomyxoma peritonei). <i>Journal of Surgical Oncology</i> , 2008, 98, 277-282.	0.8	193
99	Consensus statement on peritoneal mesothelioma. <i>Journal of Surgical Oncology</i> , 2008, 98, 268-272.	0.8	92
100	The Fifth International Workshop on Peritoneal Surface Malignancy (Milan, Italy, December 4-6, 2006): methodology of disease-specific consensus. <i>Journal of Surgical Oncology</i> , 2008, 98, 258-262.	0.8	29
101	Morbidity, toxicity, and mortality classification systems in the local regional treatment of peritoneal surface malignancy. <i>Journal of Surgical Oncology</i> , 2008, 98, 253-257.	0.8	84
102	Technical aspects of cytoreductive surgery. <i>Journal of Surgical Oncology</i> , 2008, 98, 232-236.	0.8	20
103	The Delphi approach to Attain consensus in methodology of local regional therapy for peritoneal surface malignancy. <i>Journal of Surgical Oncology</i> , 2008, 98, 217-219.	0.8	17
104	The eligibility for local regional treatment of peritoneal surface malignancy. <i>Journal of Surgical Oncology</i> , 2008, 98, 220-223.	0.8	37
105	Hyperthermic intraperitoneal chemotherapy: Nomenclature and modalities of perfusion. <i>Journal of Surgical Oncology</i> , 2008, 98, 242-246.	0.8	122
106	The consensus statement on the locoregional treatment of abdominal sarcomatosis. <i>Journal of Surgical Oncology</i> , 2008, 98, 291-294.	0.8	36
107	The intraoperative staging systems in the management of peritoneal surface malignancy. <i>Journal of Surgical Oncology</i> , 2008, 98, 228-231.	0.8	104
108	Preoperative investigations in the management of peritoneal surface malignancy with cytoreductive surgery and perioperative intraperitoneal chemotherapy: Expert consensus statement. <i>Journal of Surgical Oncology</i> , 2008, 98, 224-227.	0.8	78

#	ARTICLE	IF	CITATIONS
109	Postoperative residual disease evaluation in the locoregional treatment of peritoneal surface malignancy. <i>Journal of Surgical Oncology</i> , 2008, 98, 237-241.	0.8	56
110	Hyperthermic intraperitoneal chemotherapy with and without cytoreductive surgery for epithelial ovarian cancer. <i>Journal of Surgical Oncology</i> , 2008, 98, 283-290.	0.8	56
111	Pseudomyxoma Peritonei: Clinical Pathological and Biological Prognostic Factors in Patients Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC). <i>Annals of Surgical Oncology</i> , 2008, 15, 526-534.	0.7	167
112	Multiple Mechanisms of Telomere Maintenance Exist and Differentially Affect Clinical Outcome in Diffuse Malignant Peritoneal Mesothelioma. <i>Clinical Cancer Research</i> , 2008, 14, 4134-4140.	3.2	61
113	Multicystic peritoneal mesothelioma treated by surgical cytoreduction and hyperthermic intra-peritoneal chemotherapy (HIPEC). <i>In Vivo</i> , 2008, 22, 153-7.	0.6	17
114	Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in the Management of Peritoneal Surface Malignancies of Colonic Origin: A Consensus Statement. <i>Annals of Surgical Oncology</i> , 2007, 14, 128-133.	0.7	390
115	Circulating CA125 in Patients with Peritoneal Mesothelioma Treated with Cytoreductive Surgery and Intraperitoneal Hyperthermic Perfusion. <i>Annals of Surgical Oncology</i> , 2007, 14, 500-508.	0.7	72
116	Prognostic Value of Circulating Tumor Markers in Patients with Pseudomyxoma Peritonei Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. <i>Annals of Surgical Oncology</i> , 2007, 14, 2300-2308.	0.7	87
117	Impact of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy on Systemic Toxicity. <i>Annals of Surgical Oncology</i> , 2007, 14, 2550-2558.	0.7	69
118	Multicystic and Well-differentiated Papillary Peritoneal Mesothelioma Treated by Surgical Cytoreduction and Hyperthermic Intra-peritoneal Chemotherapy (HIPEC). <i>Annals of Surgical Oncology</i> , 2007, 14, 2790-2797.	0.7	45
119	Incidence of Postoperative Pancreatic Fistula and Hyperamylasemia after Cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy. <i>Annals of Surgical Oncology</i> , 2007, 14, 3443-3452.	0.7	23
120	Epithelioid Sarcoma: Prognostic Factors and Survival in a Series of Patients Treated at a Single Institution. <i>Annals of Surgical Oncology</i> , 2007, 14, 3542-3551.	0.7	86
121	Morbidity and Quality of Life following Cytoreduction and HIPEC. , 2007, 134, 403-418.		10
122	Advances in Clinical Research and Management of Diffuse Peritoneal Mesothelioma. , 2007, 169, 137-155.		3
123	Survivin is Highly Expressed and Promotes Cell Survival in Malignant Peritoneal Mesothelioma. <i>Analytical Cellular Pathology</i> , 2007, 29, 453-466.	0.7	35
124	Cytoreduction combined with intraperitoneal hyperthermic perfusion chemotherapy in advanced/recurrent ovarian cancer patients: The experience of National Cancer Institute of Milan. <i>European Journal of Surgical Oncology</i> , 2006, 32, 671-675.	0.5	105
125	CDX-2 expression in pseudomyxoma peritonei: a clinicopathological study of 42 cases. <i>Histopathology</i> , 2006, 49, 381-387.	1.6	46
126	Prognostic Analysis of Clinicopathologic Factors in 49 Patients With Diffuse Malignant Peritoneal Mesothelioma Treated With Cytoreductive Surgery and Intraperitoneal Hyperthermic Perfusion. <i>Annals of Surgical Oncology</i> , 2006, 13, 229-237.	0.7	144

#	ARTICLE	IF	CITATIONS
127	Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion. <i>Cancer</i> , 2006, 106, 1144-1153.	2.0	234
128	Bowel Complications in 203 Cases of Peritoneal Surface Malignancies Treated With Peritonectomy and Closed-Technique Intraperitoneal Hyperthermic Perfusion. <i>Annals of Surgical Oncology</i> , 2005, 12, 910-918.	0.7	69
129	Diffuse malignant mesothelioma of the peritoneum. <i>Cancer</i> , 2005, 104, 2181-2188.	2.0	82
130	Peritonectomy and Intraperitoneal Hyperthermic Perfusion (IPHP): A Strategy That Has Confirmed its Efficacy in Patients with Pseudomyxoma Peritonei. <i>Annals of Surgical Oncology</i> , 2004, 11, 393-398.	0.7	157
131	Uterine Sarcoma Treated by Cytoreductive Surgery and Intraperitoneal Hyperthermic Perfusion: a Feasibility Study. <i>Journal of Chemotherapy</i> , 2004, 16, 19-22.	0.7	13
132	Peritoneal mesothelioma treated by induction chemotherapy, cytoreductive surgery, and intraperitoneal hyperthermic perfusion. <i>Journal of Surgical Oncology</i> , 2003, 83, 147-153.	0.8	77
133	Chordoma: Natural History and Results in 28 Patients Treated at a Single Institution. <i>Annals of Surgical Oncology</i> , 2003, 10, 291-296.	0.7	204
134	Preoperative chemoradiation in patients with resectable rectal cancer: Results on tumor response. <i>Annals of Surgical Oncology</i> , 2002, 9, 444-449.	0.7	28
135	Post-absorptive and insulin-mediated muscle protein metabolism in liver-transplanted patients. <i>Acta Diabetologica</i> , 2002, 39, 203-208.	1.2	6
136	Preoperative chemoradiation in patients with resectable rectal cancer: Results on tumor response. , 2002, 9, 444.		1
137	Contribution of reduced insulin sensitivity and secretion to the pathogenesis of hepatogenous diabetes: Effect of liver transplantation. <i>Hepatology</i> , 2000, 31, 694-703.	3.6	114
138	Surgical Strategies in Colorectal Cancer Metastatic to the Liver. <i>Tumori</i> , 2000, 86, 1-7.	0.6	3
139	Preoperative radiation therapy for patients with T2-T3 carcinoma of the middle-to-lower rectum. , 1999, 86, 398-404.		43
140	Effect of liver transplantation in cirrhotic diabetic patients. <i>Transplantation Proceedings</i> , 1998, 30, 1868.	0.3	2
141	Renal-splenic shunt for infrahepatic caval occlusion after piggy-back liver transplantation. <i>Transplant International</i> , 1997, 10, 392-394.	0.8	3
142	Prophylaxis against HCV recurrence after liver transplantation: Effect of interferon and ribavirin combination. <i>Transplantation Proceedings</i> , 1997, 29, 519-521.	0.3	92
143	Impact of Distal Clearance Margin on Oncologic Outcome after Restorative Resection of the Rectum. <i>Tumori</i> , 1997, 83, 907-911.	0.6	9
144	Renal-splenic shunt for intrahepatic caval occlusion after piggy-back liver transplantation. <i>Transplant International</i> , 1997, 10, 392-394.	0.8	3

#	ARTICLE	IF	CITATIONS
145	Surgical treatment of locally recurrent rectal carcinoma. Diseases of the Colon and Rectum, 1997, 40, 1421-1424.	0.7	63
146	Preoperative serum levels of wild-type and hepatitis B e antigen-negative hepatitis B virus (HBV) and graft infection after liver transplantation for HBV-related hepatocellular carcinoma. Journal of Viral Hepatitis, 1997, 4, 235-242.	1.0	6
147	Metabolic effects of liver transplantation in cirrhotic patients.. Journal of Clinical Investigation, 1997, 99, 692-700.	3.9	45
148	Regulation of glucose homeostasis in humans with denervated livers.. Journal of Clinical Investigation, 1997, 100, 931-941.	3.9	95
149	Preoperative radiotherapy for resectable cancer of the middle-distal rectum: its effect on the primary lesion as determined by endorectal ultrasound using flexible echo colonoscope. International Journal of Colorectal Disease, 1996, 11, 283-286.	1.0	27
150	Avidin-biotin system in Radioimmunoguided surgery for colorectal cancer. Diseases of the Colon and Rectum, 1994, 37, 335-343.	0.7	14
151	Surgery for colorectal cancer guided by radiodetecting probe. Clinical evaluation using monoclonal antibody B72.3. The European Journal of Surgery, 1991, 157, 485-8.	1.0	4